Showing results (31-40 of 199) with videos related to
Sort By:
Pageof 20
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2011
Thunder and lightning: immunotherapy and oncolytic viruses collideAlan Melcher, Kelley Parato, Cliona M Rooney, et al.Immunobiology|December 19, 2007
Matrix protein mediated shutdown of host cell metabolism limits vesicular stomatitis virus-induced interferon-alpha responses to plasmacytoid dendritic cellsZoe Waibler, Claudia N Detje, John C Bell, et al.Journal of Virology|March 21, 2014
Vesiculovirus neutralization by natural IgM and complementMulu Z Tesfay, Arun Ammayappan, Mark J Federspiel, et al.Current Opinion in Molecular Therapeutics|January 30, 2008
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?Marianne M Stanford, Caroline J Breitbach, John C Bell, et al.Molecular Therapy Oncolytics|June 14, 2019
An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In VivoJosh Del Papa, Julia Petryk, John C Bell, et al.Cytokine & Growth Factor Reviews|March 12, 2010
Novel oncolytic viruses: riding high on the next wave?Marianne M Stanford, John C Bell, Markus J V Vähä-KoskelaCommunications Medicine|May 23, 2022
Advances in oncolytic virotherapyStephen J Russell, John C Bell, Christine E Engeland, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 5, 2008
Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligandKaren L Mossman, M Firoz Mian, Nicole M Lauzon, et al.Expert Opinion on Biological Therapy|April 17, 2020
Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneityAdrian Pelin, Stephen Boulton, Levi A Tamming, et al.Nature Reviews. Cancer|November 19, 2005
Recent progress in the battle between oncolytic viruses and tumoursKelley A Parato, Donna Senger, Peter A J Forsyth, et al.Pageof 20